Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Phase 3

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: QL2109
Drug: Pomalidomide
Drug: Dexamethasone
Drug: DARZALEX FASPRO®

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-19

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 284

Registration Number: NCT06742138

Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery

Not Applicable

Recruiting

Conditions: Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin Chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery

Interventions: Drug: Dexamethasone
Drug: Chymotrypsin

First Posted Date: 2024-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: B.P. Koirala Institute of Health Sciences

Target Recruit Count: 50

Registration Number: NCT06713733

Locations: 🇳🇵
Bp Koirala Institute of Health Sciences, Dharān Bāzār, Koshi, Nepal

Effect of Timing of Dexamethasone During Induction on Postoperative Outcomes

Phase 4

Not yet recruiting

Conditions: Postoperative Nausea and Vomiting (PONV)
Postoperative Pain
Inflammatory Response to Wounding
Hyperglycemia Drug Induced
Hypotension on Induction
Timing of Dexamethasone Administration

Interventions: Drug: Dexamethasone

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: AABDI Mohammed

Target Recruit Count: 300

Registration Number: NCT06685991

Melflufen for Elderly Patients With Relapsed Myeloma

Phase 2

Not yet recruiting

Conditions: Relapse Multiple Myeloma

Interventions: Drug: Melflufen
Drug: Dexamethasone

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-13

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 30

Registration Number: NCT06682637

Locations: 🇮🇹
A.O.U. delle Marche, Ancona, Italy
🇮🇹
Ospedale Nuovo di Legnano, Legnano, Italy
🇮🇹
Ospedale Niguarda, Milano, Italy

and more 7 locations

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Phase 3

Not yet recruiting

Conditions: Multiple Myeloma
Newly Diagnosed Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 520

Registration Number: NCT06679101

Open-Label Extension of EryDex Study IEDAT-04-2022

Phase 3

Recruiting

Conditions: Ataxia Telangiectasia

Interventions: Drug: Dexamethasone sodium phosphate

First Posted Date: 2024-10-30

Last Posted Date: 2024-12-20

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 106

Registration Number: NCT06664853

Locations: 🇩🇪
University Hospital Frankfurt, Pediatric and Adolescent Clinic, Frankfurt, Germany
🇮🇹
Spedali Civili di Brescia, Pediatric immunology department, Brescia, Italy
🇩🇪
Tübingen University Hospital, Division Translational Genomics of Neurodegenerative Diseases, Tübingen, Bade-Würtenberg, Germany

and more 14 locations

Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)

Interventions: Drug: Elranatamab
Drug: Mezigdomide
Drug: Dexamethasone

First Posted Date: 2024-10-17

Last Posted Date: 2024-11-15

Lead Sponsor: YOUNGIL KOH

Target Recruit Count: 75

Registration Number: NCT06645678

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms

Phase 2

Not yet recruiting

Conditions: Esophageal Stricture
Esophageal Neoplasms

Interventions: Drug: Tranilast
Drug: Dexamethasone

First Posted Date: 2024-10-16

Last Posted Date: 2024-11-14

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 394

Registration Number: NCT06643689

Locations: 🇨🇳
Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China
🇨🇳
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Shaoxing Central Hospital, Shaoxing, Zhejiang, China